Jean-Philippe Pradère

Jean-Philippe Pradère

Auto-generated profile, based on publicly available information

Jean-Philippe Pradère

Institut National de la Santé et de la Recherche Médicale (INSERM) U1048, Institute of Cardiovascular and Metabolic Disease, Toulouse, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
IMIngmar Mederacke
Ingmar Mederacke
CHChristine C. Hsu
Christine C. Hsu
JTJuliane S. Troeger
Juliane S. Troeger
PHPeter Huebener
Peter Huebener
XMXueru Mu
Xueru Mu
RSRobert F. Schwabe
Robert F. Schwabe
Although organ fibrosis causes significant morbidity and mortality in chronic diseases, the lack of detailed knowledge about specific cellular contributors mediating fibrogenesis hampers the design of effective antifibrotic therapies. Different cellular sources, including tissue-resident and bone marrow-derived fibroblasts, pericytes and epithelial cells, have been suggested to give rise to myofibroblasts, but their relative contributions remain controversial, with profound differences between organs and different diseases. Here we employ a novel Cre-transgenic mouse that marks 99% of hepatic stellate cells (HSCs), a liver-specific pericyte population, to demonstrate that HSCs give rise to 82–96% of myofibroblasts in models of toxic, cholestatic and fatty liver disease. Moreover, we exclude that HSCs function as facultative epithelial progenitor cells in the injured liver. On the basis these findings, HSCs should be considered the primary cellular target for antifibrotic therapies across all types of liver disease.

1 April 2012 in Cancer Cell
Verified
Journal Article
Closed access
DDDianne H. Dapito
Dianne H. Dapito
AMAli Mencin
Ali Mencin
GGGeum-Youn Gwak
Geum-Youn Gwak
JPJean-Philippe Pradere
Jean-Philippe Pradere
MJMyoung-Kuk Jang
Myoung-Kuk Jang
RSRobert F. Schwabe
Robert F. Schwabe

1 January 2015 in Cell
Verified
Journal Article
Closed access
DWDaniel L. Worthley
Daniel L. Worthley
MCMichael Churchill
Michael Churchill
JCJocelyn T. Compton
Jocelyn T. Compton
YTYagnesh Tailor
Yagnesh Tailor
MRMeenakshi Rao
Meenakshi Rao
TWTimothy Wang
Timothy Wang

28 March 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
JPJean-Philippe Pradere
Jean-Philippe Pradere
JKJohannes Kluwe
Johannes Kluwe
SMSamuele De Minicis
Samuele De Minicis
JJJing-Jing Jiao
Jing-Jing Jiao
GGGeum-Youn Gwak
Geum-Youn Gwak
RSRobert F. Schwabe
Robert F. Schwabe
Although it is well established that hepatic macrophages play a crucial role in the development of liver fibrosis, the underlying mechanisms remain largely elusive. Moreover, it is not known whether other mononuclear phagocytes such as dendritic cells (DCs) contribute to hepatic stellate cell (HSC) activation and liver fibrosis. We show for the first time that hepatic macrophages enhance myofibroblast survival in a nuclear factor kappa B (NF-κB)–dependent manner and thereby promote liver fibrosis. Microarray and pathway analysis revealed no induction of HSC activation pathways by hepatic macrophages but a profound activation of the NF-κB pathway in HSCs. Conversely, depletion of mononuclear phagocytes during fibrogenesis in vivo resulted in suppressed NF-κB activation in HSCs. Macrophage-induced activation of NF-κB in HSCs in vitro and in vivo was mediated by interleukin (IL)−1 and tumor necrosis factor (TNF). Notably, IL-1 and TNF did not promote HSC activation but promoted survival of activated HSCs in vitro and in vivo and thereby increased liver fibrosis, as demonstrated by neutralization in coculture experiments and genetic ablation of IL-1 and TNF receptor in vivo . Coculture and in vivo ablation experiments revealed only a minor contribution to NF-κB activation in HSCs by DCs, and no contribution of DCs to liver fibrosis development, respectively. Conclusion : Promotion of NF-κB–dependent myofibroblast survival by macrophages but not DCs provides a novel link between inflammation and fibrosis. (Hepatology 2013;58:1461–1473)

1 October 2012 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JTJuliane S. Troeger
Juliane S. Troeger
IMIngmar Mederacke
Ingmar Mederacke
GGGeum–Youn Gwak
Geum–Youn Gwak
DDDianne H. Dapito
Dianne H. Dapito
XMXueru Mu
Xueru Mu
RSRobert F. Schwabe
Robert F. Schwabe
Background & Aims Activated hepatic stellate cells (HSCs), the main fibrogenic cell type in the liver, undergo apoptosis after cessation of liver injury, which contributes to resolution of fibrosis. In this study, we investigated whether HSC deactivation constitutes an additional mechanism of liver fibrosis resolution. Methods HSC activation and deactivation were investigated by single-cell PCR and genetic tracking in transgenic mice that expressed a tamoxifen-inducible CreER under control of the endogenous vimentin promoter (Vimentin-CreER). Results Single-cell quantitative polymerase chain reaction demonstrated activation of almost the entire HSC population in fibrotic livers, and a gradual decrease of HSC activation during fibrosis resolution, indicating deactivation of HSCs. Vimentin-CreER marked activated HSCs, demonstrated by a 6- to 16-fold induction of a membrane-bound green fluorescent protein (mGFP) Cre-reporter after injection of carbon tetrachloride, in liver and isolated HSCs, and a shift in localization of mGFP-marked HSCs from peri-sinusoidal to fibrotic septa. Tracking of mGFP-positive HSCs revealed the persistence of 40%–45% of mGFP expression in livers and isolated HSCs 30–45 days after carbon tetrachloride was no longer administered, despite normalization of fibrogenesis parameters; these findings confirm reversal of HSC activation. After fibrosis resolution, mGFP expression was observed again in desmin-positive peri-sinusoidal HSCs; no mGFP expression was detected in hepatocytes or cholangiocytes, excluding mesenchymal-epithelial transition. Notably, reverted HSCs remained in a primed state, with higher levels of responsiveness to fibrogenic stimuli. Conclusions In mice, reversal of HSC activation contributes to termination of fibrogenesis during fibrosis resolution, but results in higher responsiveness of reverted HSCs to recurring fibrogenic stimulation.

1 July 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
LMLaurens A. van Meeteren
Laurens A. van Meeteren
PRPaula Ruurs
Paula Ruurs
CSCatelijne Stortelers
Catelijne Stortelers
PBPeter Bouwman
Peter Bouwman
MRMarga A. van Rooijen
Marga A. van Rooijen
JJJos Jonkers
Jos Jonkers
Autotaxin (ATX), or nucleotide pyrophosphatase-phosphodiesterase 2, is a secreted lysophospholipase D that promotes cell migration, metastasis, and angiogenesis. ATX generates lysophosphatidic acid (LPA), a lipid mitogen and motility factor that acts on several G protein-coupled receptors. Here we report that ATX-deficient mice die at embryonic day 9.5 (E9.5) with profound vascular defects in yolk sac and embryo resembling the Galpha13 knockout phenotype. Furthermore, at E8.5, ATX-deficient embryos showed allantois malformation, neural tube defects, and asymmetric headfolds. The onset of these abnormalities coincided with increased expression of ATX and LPA receptors in normal embryos. ATX heterozygous mice appear healthy but show half-normal ATX activity and plasma LPA levels. Our results reveal a critical role for ATX in vascular development, indicate that ATX is the major LPA-producing enzyme in vivo, and suggest that the vascular defects in ATX-deficient embryos may be explained by loss of LPA signaling through Galpha13.